Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Perspectives on the management of coronary artery disease in India. Heart (2007) 0.99

Acute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc (2009) 0.93

Factors related to in-hospital heart failure are very different for unstable angina and non-ST elevation myocardial infarction. Heart Vessels (2009) 0.82

Simple principles of clinical trials remain powerful. JAMA (2005) 0.76

Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction. Curr Cardiol Rev (2008) 0.75

Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc (2014) 0.75

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag (2006) 0.75

Reviparin in acute myocardial infarction. JAMA (2005) 0.75

Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI. ACP J Club (2005) 0.75

New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications. Vasc Health Risk Manag (2008) 0.75

Contemporary therapy of acute ST-elevation myocardial infarction. Tex Heart Inst J (2009) 0.75

Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation. Therap Adv Gastroenterol (2017) 0.75

Reviparin in acute myocardial infarction. JAMA (2005) 0.75

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Genetics of gene expression and its effect on disease. Nature (2008) 21.35

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19

Variations in DNA elucidate molecular networks that cause disease. Nature (2008) 12.04

Universal definition of myocardial infarction. Circulation (2007) 11.69

An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74

MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell (2007) 5.67

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet (2007) 4.74

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol (2008) 4.68

A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet (2007) 4.46

Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell (2013) 4.45

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74

Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med (2015) 3.18

Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09

A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res (2011) 3.00

Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet (2009) 2.97

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85

Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation (2010) 2.74

BioMagResBank database with sets of experimental NMR constraints corresponding to the structures of over 1400 biomolecules deposited in the Protein Data Bank. J Biomol NMR (2003) 2.74

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64

China's facility-based birth strategy and neonatal mortality: a population-based epidemiological study. Lancet (2011) 2.64

Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics (2005) 2.61

QTLNetwork: mapping and visualizing genetic architecture of complex traits in experimental populations. Bioinformatics (2008) 2.57

CsrA and three redundant small RNAs regulate quorum sensing in Vibrio cholerae. Mol Microbiol (2005) 2.56

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52

Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40

ToxR regulon of Vibrio cholerae and its expression in vibrios shed by cholera patients. Proc Natl Acad Sci U S A (2003) 2.29

Mapping the genetic architecture of complex traits in experimental populations. Bioinformatics (2007) 2.27

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation (2004) 2.26

Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol (2005) 2.21

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20

Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19

Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18

Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15

A paired-end sequencing strategy to map the complex landscape of transcription initiation. Nat Methods (2010) 2.14

Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med (2007) 2.14